leadf
logo-loader
view4D pharma PLC

4D pharma inks clinical trial collaboration and supply agreement with Merck and Pfizer

As part of the tie-up, 4D pharma will start a clinical trial this year BAVENCIO, a drug for advanced or metastatic urothelial carcinoma

4D pharma PLC -

4D pharma PLC (LON:DDDD) has signed a clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc.

As part of the tie-up, 4D pharma will start a clinical trial this year with BAVENCIO, a drug for advanced or metastatic urothelial carcinoma developed by Merck and Pfizer, in combination with UK group’s MRx0518.

"With this second clinical trial collaboration for MRx0518 with a leading immune checkpoint inhibitor, 4D is able to evaluate MRx0518 in a new combination and earlier treatment setting,” said 4D chief executive Duncan Peyton.

MRx0518 has already generated “promising” early clinical data in harness with blockbuster cancer drug Keytruda, while its potential is also being assessed as a single therapy.

CEO Peyton said the latest collaboration would allow its scientists “to continue to build a broad understanding of the safety and efficacy of MRx0518 across a range of solid tumours and stages of the disease”.

He added: "The combination of MRx0518 with BAVENCIO has the potential to further enhance the positive clinical outcomes achieved by BAVENCIO for the significant number of patients in this treatment setting."

Working in the emerging area of the human microbiome (the bacteria that reside mainly in the gut), 4D has developed Live Biotherapeutics — products that contain live organisms such as human commensal bacteria.

The approach focuses on single strains to assess specific mechanisms of action targeting a defined disease pathway.

Even variations between different strains of bacteria of the same species are assessed and exploited.

Peyton says superficially identical bacteria can sometimes differ up to 20% in their gene content, and therefore may have highly different functional profiles.

Toxicity has always been a major impediment to the success of new drugs.

In developing its Live Biotherapeutics, 4D has isolated bacteria from healthy human donors which are expected to have “highly attractive safety profiles”.

Quick facts: 4D pharma PLC

Price: 123.0755 GBX

LSE:DDDD
Market: LSE
Market Cap: £1.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

4d pharma says Merck KGaA and Pfizer cancer collaboration is 'big step forward'

4D pharma PLC's (LON:DDDD) chief executive Duncan Peyton talks to Proactive London's Katie Pilbeam about the clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc. Peyton says 'it's another step forward in how we work and expand our oncology franchise' which will...

3 weeks, 2 days ago

2 min read